US-Listed Public Company Profile built from SEC and market records · June 2026

NEUROCRINE BIOSCIENCES INC (NBIX)

$146.00 +0.09% NASDAQ: NBIX · 15-min delayed

SAN DIEGO, California
Public · NASDAQ: NBIX
2,000 employees

Visit website Follow

$17.7BMarket cap

$2.9BRevenue · FY2025

$478.6MNet income

2,000Employees

NBIXNASDAQ

1996IPO

About NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: NBIX
Employees: 2,000
IPO date: May 23, 1996
Headquarters: 6027 EDGEWOOD BEND COURT
SAN DIEGO, California 92130
Phone: (858) 617-7600
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 549300FECER0XBN49756

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Is Neurocrine Biosciences Inc an American company? Yes. Neurocrine Biosciences Inc is incorporated in Delaware, United States and headquartered in San Diego, California. Its legal-entity record reports no foreign parent — the company is independently American-owned.

Registry IDs

Ticker: NBIX Nasdaq
SEC CIK: 914475
LEI: 549300FECER0XBN49756
EIN: 330525145
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Neurocrine Biosciences Inc’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/neurocrine-biosciences-inc/"><img src="https://americancompanies.com/badge/neurocrine-biosciences-inc.svg" alt="Neurocrine Biosciences Inc — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow NEUROCRINE BIOSCIENCES INC and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $2.9B
Net income: $478.6M
Total assets: $4.6B
Market cap: $17.7B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: NBIX

$146.00 +0.09%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$123.10 $185.50

52-week range

Market cap: $17.7B
Shares outstanding: 121.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: May 23, 1996

Neurocrine Biosciences Inc (NBIX) Stock Price

Profitable — net income of $478.6M in FY2025.
Trading 21% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review NEUROCRINE BIOSCIENCES INC.

Write a review

Newsroom

News about NEUROCRINE BIOSCIENCES INC

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? Zacks Investment Research · 2026-10-27 · neutral Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? Zacks Investment Research · 2026-10-26 · neutral Where Will Neurocrine Biosciences Be in 5 Years? The Motley Fool · 2026-10-25 · positive Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight GlobeNewswire Inc. · 2026-10-15 · positive Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term Zacks Investment Research · 2026-10-14 · positive NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? Zacks Investment Research · 2026-10-13 · positive

News & sentiment via Polygon.io

FAQ

Neurocrine Biosciences Inc: frequently asked questions

Is Neurocrine Biosciences Inc an American company?

Yes — Neurocrine Biosciences Inc is an American company. Neurocrine Biosciences Inc is incorporated in Delaware, United States and headquartered in San Diego, California. Its legal-entity record reports no foreign parent — the company is independently American-owned.

Where is Neurocrine Biosciences Inc incorporated?

Neurocrine Biosciences Inc is legally incorporated in Delaware, United States, according to its GLEIF legal-entity record.

Who owns Neurocrine Biosciences Inc?

Neurocrine Biosciences Inc reports no parent company in its legal-entity record — it is independently owned rather than a subsidiary.

Is Neurocrine Biosciences Inc traded on a US stock exchange?

Yes — Neurocrine Biosciences Inc trades under the ticker NBIX on the NASDAQ.

Where is Neurocrine Biosciences Inc headquartered?

Neurocrine Biosciences Inc is headquartered in San Diego, California, United States.

Is Neurocrine Biosciences Inc publicly traded?

Yes — Neurocrine Biosciences Inc is a publicly traded company. Its stock trades under the ticker symbol NBIX on the NASDAQ.

What does Neurocrine Biosciences Inc do?

Neurocrine Biosciences Inc is an American Pharmaceuticals company in the Health & Beauty sector.